Late-Breaking Abstract 5: Results from a 2nd interim OS analysis in OCEANS: A randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)

C Aghajanian,S Blank,B Goff,P Judson,L Nycum,M Sovak,J Yi,A Husain

doi:10.1016/j.ygyno.2012.03.038

Late-Breaking Abstract 5: Results from a 2nd interim OS analysis in OCEANS: A randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)

C Aghajanian, S Blank + Show 6 more

https://doi.org/10.1016/j.ygyno.2012.03.038

Copy DOI

Journal: Gynecologic Oncology	Publication Date: May 17, 2012
Citations: 8

Affiliation: Memorial Sloan Kettering Cancer Center, New York University, University of Washington, Moffitt Cancer Center

#Fallopian Tube Cancer #Platinum-sensitive Recurrent Epithelial Ovarian Cancer + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Late-Breaking Abstract 5: Results from a 2nd interim OS analysis in OCEANS: A randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Gynecologic Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.